What does xCures' product actually do?

xCures integrates patient records from thousands of incompatible sources—hospitals, labs, imaging centers, electronic medical records—and transforms unstructured documents (including scanned records, pictures, and narrative notes full of human entry errors) into structured, decision-ready clinical information. The company calls this capability its 'Clinical Clarity Engine.'

The company has 25 enterprise customers, including lab diagnostic companies such as Exact Sciences, Caris Life Sciences, and Novocure. Large hospital networks use it for operating-room scheduling and screening for patient comorbidities; telehealth providers without robust electronic health record systems use it; and Medicare Advantage plans use it for population risk stratification and prior authorizations.

How fast is the company growing?

xCures grew annualized recurring revenue from roughly $3 million（約4.8億円） to $10 million（約16億円） in 2025, and is on track to break $20 million（約32億円） in 2026. The company achieved cash-flow breakeven last year but has intentionally entered a capital-burn phase to build its team for its 2027 business pipeline.

Back to articles

Healthcare AI startup xCures closes $46 million（約74億円） Series B to organize messy patient data, more than doubling its valuation since late 2023.

Crunchbase News AI1d ago6 min read

Key takeaway

xCures, a healthcare AI startup that organizes fragmented patient medical records for hospitals and health networks, has raised $46 million（約74億円） in Series B funding at a $127 million（約200億円） valuation. The company's technology converts messy, scattered patient data into structured clinical insights that support surgical planning, diagnosis, and administrative decisions across the U.S. healthcare system.

Summaries like this, in your inbox every morning.

3 Key Points

What happened
xCures, which uses AI to structure patient medical records, raised $46 million（約74億円） in a Series B round led by Innovius Capital. The funding brings total capital to more than $76 million（約120億円） since 2018 and values the company at $127 million（約200億円） post-money—more than double its previous Series A valuation of $127 million（約200億円） from December 2023.
Why it matters
Healthcare organizations spend vast sums managing scattered, messy patient data across thousands of hospitals and labs. xCures' technology converts unstructured records into structured, decision-ready information—a task the company's CEO estimates puts it three to five years ahead of competitors. The company has processed more than 300 million medical records from more than 550,000 healthcare locations and supports clinical decisions for millions of patients.
What to watch
xCures grew annualized recurring revenue from roughly $3 million（約4.8億円） to $10 million（約16億円） in 2025 and expects to reach $20 million（約32億円） by 2026. The 25-member enterprise customer base includes lab diagnostics firms (Exact Sciences, Caris Life Sciences, Novocure) and large hospital networks using the tool for operating-room scheduling, risk stratification, and administrative automation.

FAQ

What does xCures' product actually do?: xCures integrates patient records from thousands of incompatible sources—hospitals, labs, imaging centers, electronic medical records—and transforms unstructured documents (including scanned records, pictures, and narrative notes full of human entry errors) into structured, decision-ready clinical information. The company calls this capability its 'Clinical Clarity Engine.'
Who is using xCures?: The company has 25 enterprise customers, including lab diagnostic companies such as Exact Sciences, Caris Life Sciences, and Novocure. Large hospital networks use it for operating-room scheduling and screening for patient comorbidities; telehealth providers without robust electronic health record systems use it; and Medicare Advantage plans use it for population risk stratification and prior authorizations.
How fast is the company growing?: xCures grew annualized recurring revenue from roughly $3 million（約4.8億円） to $10 million（約16億円） in 2025, and is on track to break $20 million（約32億円） in 2026. The company achieved cash-flow breakeven last year but has intentionally entered a capital-burn phase to build its team for its 2027 business pipeline.

Discussion

No discussion yet for this article

Stay ahead with AI news

Get curated AI news from 200+ sources delivered daily to your inbox. Free to use.

Get Started Free

Free · takes 30 seconds · unsubscribe anytime

5 minutes a day. The AI essentials.

200+ sources · Email / LINE / Slack

Get it free →